Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans

Authors

  • Renato V. Iozzo,

    1.  Department of Pathology, Anatomy and Cell Biology, and the Cancer Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
    Search for more papers by this author
  • Liliana Schaefer

    1.  Pharmazentrum Frankfurt, Institut für Allgemeine Pharmakologie und Toxikologie/ZAFES, Klinikum der JW Goethe-Universität Frankfurt am Main, Germany
    Search for more papers by this author

R. V. Iozzo, Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, 1020 Locust Street, Room 249 JAH, Philadelphia, PA 19107, USA
Fax: +1 215 923 7969
Tel: +1 215 503 2208
E-mail: iozzo@mail.jci.tju.edu
or
L. Schaefer, Pharmazentrum Frankfurt Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der JW Goethe-Universität Frankfurt am Main Haus 74, Z.3.108a, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
Fax: +49 69 6301 83027
Tel: +49 69 6301 7899
E-mail: schaefer@med.uni-frankfurt.de

Abstract

The small leucine-rich proteoglycans (SLRPs) are involved in many aspects of mammalian biology, both in health and disease. They are now being recognized as key signaling molecules with an expanding repertoire of molecular interactions affecting not only growth factors, but also various receptors involved in controlling cell growth, morphogenesis and immunity. The complexity of SLRP signaling and the multitude of affected signaling pathways can be reconciled with a hierarchical affinity-based interaction of various SLRPs in a cell- and tissue-specific context. Here, we review this interacting network, describe new relationships of the SLRPs with tyrosine kinase and Toll-like receptors and critically assess their roles in cancer and innate immunity.

Ancillary